Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Apixaban surpasses DOACs in very elderly patients

Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900

Key clinical point: Apixaban surpassed two other direct-acting oral anticoagulants in a large, observational database.

Major finding: The adjusted stroke or systemic embolism rate with apixaban was 35% less than dabigatran and 28% less than rivaroxaban.

Study details: A retrospective analysis of observational data collected in insurance claims from 53,710 U.S. octogenarians.

Disclosures: The study was funded by Bristol-Myers Squibb and Pfizer, the companies that market apixaban (Eliquis). Dr. Deitelzweig is a consultant to and speaker on behalf of Bristol-Myers Squibb and Pfizer. He is also a consultant to or speaker on behalf of Boehringer Ingelheim, Daiichi-Sankyo, Janssen, and Portola Pharmaceuticals.

Read the article here.

Citation:

Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900